Entasis Therapeutics Holdings Власний капітал 2024

Що робить Entasis Therapeutics Holdings?

Entasis Therapeutics Holdings Inc is a biopharmaceutical company focused on the development and commercialization of novel antibiotics to combat infectious diseases. The company was founded in 2015 by a team of experienced executives, researchers, and academics in the biotechnology industry specializing in the field of infectious diseases. Entasis's business model is based on the discovery and development of novel antibiotics effective against multi-drug resistant bacteria. The company utilizes its own technology platform to identify drug candidates based on the specific needs of patients and global health threats. Entasis aims to develop innovative therapies to solve global health problems and save lives. The company is focused on the development of two main categories of drug candidates: antibiotics against gram-negative bacteria and innovative combination therapies to combat antibiotic resistance. Entasis has developed a pipeline of high-potential antibiotic candidates, including ETX2514, a next-generation antibiotic to combat beta-lactam resistance, and recently SUL-digenem, a combination of one of the most commonly used antibiotics, sulbactam, and their newly developed antibiotic durlobactam. The company also emphasizes strategic partnerships, such as its current partnership with GARDP, a joint venture between the World Health Organization and the Drugs for Neglected Diseases Initiative. Entasis has also developed a range of products to combat infectious diseases. One of these products is the antibiotic zoliflodacin, used for the treatment of sexually transmitted diseases such as gonorrhea. It is in the late stage of clinical development and could soon enter the market. Another product is sulbactam-durlobactam, used for the treatment of infections caused by gram-negative bacteria, currently in clinical development. The company has a strong presence in the academic world and actively builds partnerships with leading institutions to support its research and development efforts. It collaborates with universities and research institutes in the USA and Europe to develop new drug candidates and therapies with the potential to revolutionize the treatment of infectious diseases. Entasis Therapeutics Holdings Inc is an innovative biopharmaceutical company that improves global health through the development of novel antibiotics and combination therapies. The company has an impressive pipeline of antibiotic candidates targeting infections caused by multi-drug resistant bacteria. Through collaborative agreements and the latest scientific advancements, Entasis hopes to develop even more life-saving medications in the future. Entasis Therapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.